DBV Technologies S.A. (NASDAQ:DBVT) Receives Average Recommendation of “Moderate Buy” from Analysts

Shares of DBV Technologies S.A. (NASDAQ:DBVT) have received a consensus recommendation of “Moderate Buy” from the seven analysts that are covering the stock, MarketBeat.com reports. One research analyst has rated the stock with a sell rating, one has given a hold rating, four have assigned a buy rating and one has given a strong buy rating to the company. The average twelve-month price target among brokers that have updated their coverage on the stock in the last year is $48.50.

Several research analysts recently weighed in on the stock. Wall Street Zen lowered shares of DBV Technologies from a “hold” rating to a “sell” rating in a research note on Saturday, July 4th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of DBV Technologies in a research note on Monday, June 29th. Citigroup reiterated an “outperform” rating on shares of DBV Technologies in a report on Friday, May 1st. Guggenheim reissued a “buy” rating and set a $51.00 price target on shares of DBV Technologies in a research report on Monday, May 4th. Finally, Citizens Jmp boosted their price target on shares of DBV Technologies from $47.00 to $55.00 and gave the company a “market outperform” rating in a report on Tuesday, June 30th.

DBV Technologies Trading Down 3.1%

NASDAQ:DBVT opened at $15.98 on Tuesday. DBV Technologies has a 1-year low of $8.51 and a 1-year high of $26.18. The business’s 50-day moving average price is $17.50 and its two-hundred day moving average price is $19.59. The firm has a market capitalization of $946.18 million, a price-to-earnings ratio of -3.58 and a beta of -0.95.

DBV Technologies (NASDAQ:DBVT) last posted its earnings results on Thursday, April 30th. The company reported ($0.56) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.14) by ($0.42). The company had revenue of $0.90 million for the quarter, compared to analyst estimates of $1.11 million. DBV Technologies had a negative return on equity of 129.88% and a negative net margin of 2,895.37%. Sell-side analysts predict that DBV Technologies will post -0.38 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently added to or reduced their stakes in the business. Allworth Financial LP bought a new stake in shares of DBV Technologies in the fourth quarter worth about $32,000. Royal Bank of Canada acquired a new stake in shares of DBV Technologies during the fourth quarter worth about $34,000. GAMMA Investing LLC lifted its holdings in shares of DBV Technologies by 38.4% during the 4th quarter. GAMMA Investing LLC now owns 2,680 shares of the company’s stock valued at $51,000 after purchasing an additional 744 shares in the last quarter. Truvestments Capital LLC lifted its holdings in shares of DBV Technologies by 71.3% during the 4th quarter. Truvestments Capital LLC now owns 3,892 shares of the company’s stock valued at $75,000 after purchasing an additional 1,620 shares in the last quarter. Finally, Persistent Asset Partners Ltd acquired a new position in shares of DBV Technologies in the 4th quarter valued at approximately $115,000. 71.74% of the stock is currently owned by institutional investors.

DBV Technologies Company Profile

DBV Technologies SA is a clinical-stage biopharmaceutical company engaged in developing immunotherapies for allergic diseases. The company specializes in epicutaneous immunotherapy, leveraging its proprietary Viaskin platform to deliver biologically active compounds across intact skin without needles or injections. Through this approach, DBV aims to modulate patients’ immune response to specific allergens, offering a potentially safer and more convenient alternative to traditional therapies.

The company’s lead product candidate, Viaskin Peanut, is designed for the treatment of peanut allergy in children and adolescents.